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Key words: Atopic dermatitis, eczema, microbiome, transcriptome, biologics Atopic dermatitis (AD) is a very common skin disease with a lifetime prevalence of 20%, and the majority of patients are children. 1, 2 With each passing year, more advances have been made in regard to understanding the pathophysiology of this disease process and developing more targeted therapies. In this article we highlight advances made in 2017 that include detailing of the microbiome and its role in skin disease, molecular endotyping, advances in cytokine signaling and patient-specific therapies, new biologics in the pipeline, and the safety profiles of recently released biologics.
THE ROLE OF THE MICROBIOME IN AD DEVELOPMENT AND DISEASE MODIFICATION
AD is a complex multifactorial disease encompassing defects in skin architecture, immune dysregulation, and skin flora changes. 3, 4 Human skin is densely colonized by a variety of natural flora influenced by the host and the surrounding environment. 5, 6 In 2017, this natural microbiome was investigated as a cause for inflammation and AD.
Given the role mast cells (MCs) play in many skin diseases, the role of the microbiome on MCs and skin maturation was investigated through mouse models. MCs are localized in the skin, originating from the bone marrow, with final differentiation occurring as a result of cytokine signaling. 7 MC phenotypes and functional profiles were compared in germ-free/pathogen-free mice that were later reconstituted with normal skin microbiota. The maturity of these cells was then compared with skin levels of stem cell factor, lipoteichoic acid, and Toll-like receptor 2 ligand, all of which are important for MC differentiation. Germ-free mice demonstrated abnormal and undifferentiated MCs that then normalized after reconstitution, indicating that by changing the microbiome environment or commensal bacterial makeup, MC maturation can be adversely affected. 8 We know that skin disease flares have been associated with a skewed microbiome, with overgrowth of Staphylococcus aureus implicated in patients with severe AD compared with a predominance of Staphylococcus epidermidis in those with more mild disease. 9 It is interesting to postulate that the abnormal microbiome of patients with AD with a predominance of S aureus would cause a skewing of MCs, leading to greater rates of sensitization and atopic disease.
Of note, other studies have commented on natural killer (NK) cells and the role this compartment of the immune system plays in AD skin architecture and susceptibility to superinfection. In dermatitis-prone mouse strains, a model of eczema herpeticum demonstrated the role of NK cells in the development of severe skin lesions. Mice predisposed to AD-like skin, as well as control mice, were infected with herpes simplex virus 1 to induce severe skin lesions. Normal mice not predisposed to skin breakdown exhibited less severe herpes simplex virus 1 lesions with improved NK cell activity compared with eczematous mice. These results suggest that a lack of dysfunctional NK cells might also play a role in the development of more severe skin superinfection in those with eczematous skin. 10 Several studies commented on the protective role of normal skin flora to keep S aureus overgrowth in check. Normal skin flora, including coagulase-negative S aureus strains with antimicrobial activity against S aureus, have been shown to be more prominent in those with healthy skin. When those strains of bacteria are introduced in a mouse model, the same antimicrobial effect is demonstrated. 11 Even more fascinating is the demonstration of introduction of these coagulase-negative S aureus strains into AD skin and the subsequent decrease in S aureus overgrowth appreciated. The long-term effects and possible benefits of transplanting flora from healthy skin to diseased skin are yet unknown, but clinical trials exploring probiotic supplementation and skin flora are underway. 12 In addition, investigation into the engineered bacteriophage endolysin as a means to decrease S aureus while leaving the other skin commensals unharmed also continues. 13 These new insights into the timing of microbiome development and the critical balance of staphylococcal species in not just the presence of disease but also disease severity described in 2017 make for very interesting prospects as potential areas for treatment and even prevention of disease.
The influence of the microbiome appears to start early in life. Kennedy et al 14 investigated bacterial RNA gene sequences from several skin sites of infants in a large birth cohort and assessed AD outcomes. The earlier the development of commensal bacteria on the skin, the less likely infants are to have AD, further supporting the notion that natural flora are beneficial and an overly hygienic environment might do more harm than good. Although birth modality has commonly been purported as a cause for changes in gut microflora, 15 this particular cohort did not note a difference in skin flora between those born vaginally or by means of cesarean section delivery. The same discussions also surround breast milk compared with cow's milk-based formula feeding. These infants also did not have differences in skin flora between the 2 modalities of feeding. Interestingly, bacterial skin growth and diversity changed over time, demonstrating the influence of age as a factor in affecting normal skin flora. Could the observation that AD frequently has changes in clinical phenotype as a patient ages be related to this concept? This is speculation but an interesting observation nonetheless.
Along the same theme of the prenatal environment affecting the microbiome of the skin, there has been some investigation into prenatal probiotic exposure and the effects on the microbiome. In an interesting letter to the editor, Avershina et al 16 reviewed a preestablished large birth cohort and found a significant reduction in AD in children exposed to probiotics in utero. The group reviewed pediatric patients both with and without AD. Within those 2 populations, they compared those prenatally exposed to probiotics and those who were not. They found that children with AD and no exposure have a divergent skin environment, with overexpression of Bifidobacterium dentium. 16 Not only does this observation support the hypothesis that patients with AD have different skin commensal makeup, but it also provides more evidence that prenatal environments might play a larger role in future skin disease than previously understood.
Another study found that pediatric patients pulled from an established AD database who had known increased S aureus colonization had increased daily inhaled corticosteroid use, increased total IgE levels, and increased percent positive skin prick test responses to aeroallergen. 17 This suggests that not only does skin commensal bacteria play a role in response to topical AD treatment but also might have more systemic effects on other atopic diseases.
Although the skin microbiome has certainly become a hot topic in the field of AD, several studies have looked into environmental influences that might be adversely affecting skin. As is well known, the hygiene hypothesis has emerged as one of the leading theories as to why the prevalence of atopic disease has skyrocketed in industrialized countries over the last few decades supported by work done with rural populations. 18, 19 As such, there has been some investigation into region-specific factors that might be contributing to pediatric AD.
Based on a previous observation that children born during specific seasons have a propensity for AD, Engebretsen et al 20 evaluated a large Danish cohort for the association between water hardness and birth seasonality. More than 50,000 children were included from this large national cohort, with detailed information on water grading where the children lived. The authors observed that early exposure to hard domestic water along with a fall/winter birth was significantly associated with a greater prevalence of AD in the first 18 months of life. They also noted a doseresponse relationship with water, meaning an increase in water hardness was associated with a greater prevalence in the area of AD. More detail into the effect of environmental exposures, such as water, on the microbiome as it pertains to the skin would be interesting to see in future studies.
EFFECTS OF SKIN BARRIER DYSFUNCTION ON AD
Taking a more focused look at the molecular environment of affected AD skin, more evidence on the role of specific gene mutations in the natural history of AD in the context of overall atopy and treatment response came to light in 2017.
Filaggrin
Filaggrin (FLG) has been shown to play a role in the skin's protective barrier with regard to preventing water loss and upholding physical integrity. Loss-of-function (LOF) mutations in the FLG gene have been described in patients with both ichthyosis vulgaris and AD. 21 In recent years, studies and clinical reviews have considered ways to prevent progression to food allergy by altering or halting the development of AD. 22, 23 In thinking about the role of FLG in this hypothesis, a large Swedish cohort of more than 3000 children was studied prospectively for associations between AD and IgE sensitization. It was found that the presence of preschool AD, irrespective of the presence of FLG mutation, predisposed children to food allergen sensitization by age 4 years and aeroallergen sensitization at age 16 years. Having an FLG mutation predisposed children to clinical peanut allergy specifically at age 4 years, further supporting the notion that a disrupted skin barrier through a specific mechanism poses later risk of sensitization. 24 Additional investigation has supported findings that LOF mutations of FLG without concurrent inflammation are enough to alter expression of proteins relevant to AD, including those involved in regulation of inflammation. Specifically, overrepresentation of kallikrein 7 was noted in addition to differences in expression of cyclophilin A and cofilin 1, all of which are implicated in skin inflammation and cell structure. These findings help to further characterize molecular patterns in patients with atopic disease. 25 These concepts tie into the notion of FLGdriven skin changes, and FLG-determined predisposition to AD as the first step in the atopic march toward development of food allergy, allergic rhinitis, and asthma.
Thymic stromal lymphopoietin
Although FLG mutations have been associated with increased AD disease severity, the rs1898671 single nucleotide polymorphism in thymic stromal lymphopoietin (TSLP) has been reported to have an association with less severe AD. 26 Chang et al 27 reported the influence of FLG and TSLP variants on AD severity and topical immunomodulator use in more than 800 children who were followed for an average of 7 years. Genotype variations were compared by grouping patients into 2 categories based on their genetic variants. Those with 2 FLG LOF mutations (homozygotes or compound heterozygotes) were compared with those with either no mutation or heterozygotes. Similarly, with regard to TSLP, patients with homozygous variants at the rs1898671 single nucleotide polymorphism were compared with those with either just a single heterozygous variant or a wild-type sequence. All patients were using topical calcineurin inhibitors (TCIs) at the start of the study. At 6-month intervals, use of topical steroids and TCIs was measured. Patients with FLG LOF homozygosity and compound heterozygotes were less likely to report any skin clearance within the previous 6 months and were more likely to use topical steroids. Among all FLG genotypes, there was a reported equal use of TCIs with a lower rate of skin clearance perhaps because of greater skin barrier dysfunction brought on by mutation that might not be directly addressed by TCIs. TSLP-homozygous patients had a lower rate of TCI use at the conclusion of the study, and those off TCIs were less likely to be receiving other treatments to control AD when compared with those with wild-type TSLP sequences. 27 Overall, these findings suggest that a targeted approach to skin clearance based on molecular makeup might play a large role in achieving relief from AD symptoms in the future.
Barrier disruption
Furthering the notion that barrier dysfunction plays a role in disease processes, a very interesting letter to the editor commented on the possible link between skin barrier dysfunction and similar structural malformations found in teeth. The Growing Up Towards Health Outcomes (GUSTO) study looked longitudinally at whether the occurrence of AD during the first year of life had an association with the risk of early childhood caries at ages 2 and 3 years. 28 In children with AD and a positive skin test result, a greater risk of caries was associated at both 2 and 3 years of age. These results suggest that molecular changes in skin composition and risk of skin disease can also be extrapolated to other damaged surface areas, particularly teeth.
EFFECT OF THERAPY ON CYTOKINE PRODUCTION
Knowing more about individual endotyping and molecular signatures as a means for guiding therapy shows promise. To add to the discussion as to whether AD is heterogeneous among patients at the biological level, Thijs et al 29 took almost 200 adults with moderate-to-severe AD and identified 4 AD patient clusters based on the inflammatory environment of the skin. These groups were identified as having (1) high pulmonary and activationregulated chemokine and T H 2 cytokine levels; (2) low CCL5 (RANTES), IFN-g, and TNF-like weak inducer of apoptosis levels; (3) low epithelial cytokine levels and low antiviral IFNb and monokine-induced by IFN-g levels; and 4) high TSLP, IL-1, and T H 2 cytokine levels. The authors propose separating patients based on a molecular phenotype to better understand differences in pathogenesis and potential response to therapy. Such separation and classification can perhaps better aide in deciding which treatment modalities would best serve the patient, again contributing to the notion of patient-specific AD therapy. 29 The use of topical therapeutics has been shown to change molecular signatures of the skin, including both tissue biomarkers and transepidermal water loss. One study enrolled 30 patients with mild-to-moderate AD in a randomized, double-blind comparison of topical steroids applied at 4 different specific sites for 14 days. These topical agents included pimecrolimus, betamethasone dipropionate, clobetasol propionate, and an emollient control. Changes between skin sites in total sign scores (erythema, edema/population, oozing/crusting, excoriation, lichenification, and dryness), water loss, and tissue biomarkers were studied. Of particular importance were the biomarkers evaluated, including IL-12, IL-22, and S100As, all of which are implicated in T H 17/T H 22-guided skin inflammation. Differences between the sites of application were noted both halfway through the study and at day 15, with topical steroids having a bigger effect in terms of restoration of epidermal hyperplasia and terminal differentiation, as well as reduction in IL-12, IL-22, and S100A levels as opposed to pimecrolimus and emollient. 30 Of note, the biggest difference in total sign scoring was noted on areas with clobetasol application, which was also the highest-potency topical steroid used in the study. Overall, these findings describe why topical therapies are effective for AD lesions with a focus on clarifying molecular pathways.With more information emerging about the molecular environment of the skin and its role in the pathogenesis of AD, cytokines specifically have become of interest as a target for AD treatment. We know that the development of AD is a compilation of immune regulation dysfunction, poor protective barrier repair, and microbiome imbalance with insults provided by our environment. 31, 32 In 2017, more groups focused on specific cytokine signaling abnormalities and their role in AD development.
For example, IL-17 receptor A has been linked to worsening inflammatory skin changes in Flg knockout mouse models, suggesting a 2-hit hypothesis in terms of severe AD. 33 The T H 17/ IL-22/IL-17 axis is also well described as pathogenic in patients with AD. 34 Connecting this pathway with other skin disorders, such as the ichthyoses, is a report from Paller et al, 35 which attempted to better characterize patients with similar skin architectural problems as those with severe AD. Analysis of skin biopsy specimens from 21 patients with ichthyosis showed similar levels of IL-2 and IL1b compared with patients with AD. IL-17-related gene induction was prominent and similar to other skin disorders, suggesting the possibility of IL-17 as a target for this group of skin disorders. Studies have also looked at measurable biomarkers of IL-17-driven pathology, including serum b-Defensin 2. 36 It seems that targeting specific cytokine pathways as a treatment modality for AD might also be applicable to other skin pathologies with similar phenotypes.
As has been previously described, IL-4 promotes the differentiation of naive CD4 cells into T H 2 subsets, thus increasing allergic inflammation. 37 IL-4 has also been implicated in wound response at the level of keratinocyte gene expression. Recent mouse models have suggested that in both an acute and chronic stimulation setting, IL-4 induced repression of fibronectin and subsequent delayed wound repair. 38 Serezani et al 38 used RNA sequencing and functional assays to determine what effect on keratinocyte wound repair there is in an allergic environment, specifically outlining changes induced by IL-4. Human keratinocytes stimulated with IL-4 resulted in a dose-dependent increased genomic expression of more than 1000 genes, including those that play a role in local dermatologic inflammatory response and cell-to-cell communication, such as those encoding CCL26, carbonic anhydrase 2, cytokine inducible SH2, and serpin peptidase inhibitor B4. This suggests that exposure can influence local skin inflammation and alter cell proliferation and survival, as well as affect cell adhesion. As such, this particular model found that IL-4 induced repression of fibronectin and impaired wound-healing responses of keratinocytes.
Increased expression of kallikrein-related peptidase 5 (KLK5) has been implicated in patients with AD and AD-like lesions caused by induction of desmosomal protein degradation and increased proinflammatory cytokines through protease-activated receptor 2 (PAR2). 39 A small sample population of 5 patients studied showed upregulated KLK5 is present in both lesional and nonlesional AD skin. Lesional AD skin showed typical epidermal changes, including acanthosis and parakeratosis, but interestingly, normal skin of patients with AD showed similar abnormalities when compared with that of healthy control subjects. In AD lesional or nonlesional skin, although there was an upregulation of KLK5, there was not persistent upregulation of PAR2. The effects of the upregulated KLK5 included abnormally reduced expression of desmoglein 1 and FLG and increased IL-8, IL-10, and TSLP expression. These changes were all independent of PAR2 and provide another example of a potential molecular target (KLK5) for therapeutic strategy. 40 We see differences and skewing in cytokine signaling in patients with AD, and we know that children with atopic disease can certainly have increased IgE levels. More has been revealed regarding this shift toward an IgE phenotype.
Czarnowicki et al 41 explored what B-cell subsets associated with IgE class-switching are associated with early pediatric AD, questioning whether early B-cell differentiation is associated with pediatric AD. Twenty-seven children with moderate-tosevere AD were compared with age-matched control subjects, with similar comparisons made in adult groups. Circulating CD19
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1 B-cell counts were lower in children with AD, whereas CD3
1 T-cell counts were greater, and interestingly, a positive correlation was seen between B-cell/T-cell ratio and nonswitched memory B cells. As expected, children with AD had greater amounts of circulating IgE. Children showed a greater propensity for T cells in the skin than adults, irrespective of AD status.
THERAPEUTIC BIOLOGICS IN THE PIPELINE
With the burst of interest among the scientific community in regard to treating AD at a molecular level and increased understanding of the molecular pathogenesis of this disease, several new biologic agents are currently in the pipeline and were explored further in 2017. Fig 1 outlines the following agents discussed.
Tralokinumab has emerged as an anti-IL-13 agent. In a phase 2b, randomized, placebo-controlled, double-blind study 204 adult patients were randomized to receive either 45, 150, or 300 mg of tralokinumab or placebo every 2 weeks, along with a topical corticosteroid for 12 weeks. Outcomes measured included Eczema Area and Severity Index (EASI) and Investigator's Global Assessment (IGA) scores in addition to patient-reported outcomes. EASI and SCORAD scores have been previously shown to correlate consistently in prospective dermatologic reviews, as opposed to using defined well-controlled weeks. 42, 43 Tralokinumab at 300 mg every 2 weeks significantly reduced EASI scores, and patients experienced improved skin clearance. These patients also reported improved quality-of-life and pruritus scores compared with those in the placebo group. Patients with a baseline increased level of IL-13 (as measured by serum dipeptidyl peptidase 4 concentrations) had more response than placebo-treated patients, with more patients reaching an IGA score of 0/1. Such results specific to a subset of those with AD might prove useful in targeting therapy. 44 There do not seem to be pharmacokinetic differences or tolerance issues with the 300-mg dose in regard to the rate of subcutaneous administration. 45 In addition, nemolizumab, an anti-IL-31 receptor A agent, has also shown promising results in reducing pruritus in patients with AD. Pruritus is a main focus of AD treatment given the propensity of protected physical trauma induced by scratching to increase barrier disruption with worsening control of AD-related inflammation. Pruritus caused by AD also has implications for sleep disturbance and poor quality of life, as demonstrated in a prospective observational study correlating patient-reported quality-of-life scores with itch or pain perception. 46 In a phase 2, randomized, double-blind, placebo-controlled 12-week trial, more than 200 adults with moderate-to-severe AD were given subcutaneous nemolizumab at doses of 0.1 mg/kg, 0.5 mg/kg, or 2.0 mg/kg or placebo every 4 weeks or an exploratory dose of 2.0 mg/kg every 8 weeks. The primary outcome measured was self-reported itch by using a daily logging system by patients. All patients who received nemolizumab had significant changes in pruritus compared with those receiving placebo, with the most effective change observed in the 2.0 mg/kg group every 4 weeks. Secondary outcomes, such as EASI scores, also showed improvement in the treatment groups; however, body surface area affected by AD was not different from that seen in the placebo group. Itch has become an area of focus because of the dramatic effects on quality of life and exacerbation of underlying skin disease. Adverse events (AEs) noted in the study between both groups were largely caused by exacerbation of AD. Additional AEs included nasopharyngitis, upper respiratory tract infection, peripheral edema, and increased creatine kinase levels. The most common adverse effects found in the treatment group included exacerbation of AD and peripheral edema. Peripheral edema was seen in 12 patients total among all treatment groups. Nemolizumab has shown promising results in this regard and remains in the pipeline as a potential future biologic therapy. 47 Ustekinumab is another agent that targets IL-12/IL-23p40 to suppress T H 1, T H 17, and T H 22 activation. It has clinical approval for use in patients with psoriasis and has demonstrated clinical efficacy and safety for that condition, but its efficacy and safety in J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 6 patients with AD are not as well known. This biologic also underwent a phase 2, double blind, placebo-controlled trial of 33 adult patients in 2017. Patients with moderate-to-severe AD were randomly assigned to either a treatment group (45 mg for patients < _100 kg or 90 mg if >100 kg) or placebo every 4 weeks. Primary end points included clinical and biopsy measures of inflammation. Higher SCORAD50 responses were noted in the treatment group, although these were not significantly different from those in the placebo group. Interestingly, when gene expression was assessed, it was demonstrated that the treatment group showed a strong and rapid modulation of T H 1 and T H 22 pathway genes with higher inhibition of T H 2 gene products 4 weeks into therapy, all suggesting a clear molecular benefit to the medication. 48 There were no serious AEs reported in the study. The 24 self-reported AEs experienced by 14 patients were classified as mild to moderate and were not significantly different between treatment arms.
Of note, however, in another randomized, phase 2, placebocontrolled trial performed with a Japanese cohort, ustekinumab did not show significant benefit for patients with severe AD, which was defined as an EASI score of at least 12. In this study 79 patients aged 20 to 65 years were enrolled in a 12-week trial in which they were administered 45 or 90 mg of ustekinumab or placebo injections at weeks 0 and 4. Follow-up evaluations continued until week 24. Primary end points included change in EASI score at week 12, with additional measures including an IGA score of 0 and changes in itch scale scores and quality-of-life index scores. Neither dose of ustekinumab showed significant differences in these measures compared with placebo, although numerically, the treatment groups had a greater percentage change in EASI scores. No significant serious adverse effects were noted. 49 Therefore ustekinumab might provide some benefit for AD, and more investigation is needed to determine which patient subset could achieve the most relief.
SAFETY PROFILING OF CURRENT BIOLOGICS
The development of new therapeutic strategies for AD has clearly spurred excitement in the field and led to additional investigation of the molecular environment of the skin and how it differs among patients. In 2017, further delineation of the safety profiles of new biologics approved by the US Food and Drug Administration came to light.
Phosphodiesterase 4 has been identified as a potential target for AD therapy because of the enzyme's involvement in proinflammatory cytokine production. 50 Crisaborole ointment 2% has emerged as an inhibitor of phosphodiesterase 4-dependent cyclic adenosine monophosphate degradation. This in turn regulates cell-signaling pathways to enhance cellular control of skin inflammation. 51 Crisaborole was approved for clinical use in 2016 or mild-to-moderate AD for both adults and children aged 2 years and older. The long-term safety profile of crisaborole ointment 2% in both children and adults with mild-to-moderate AD was profiled in a multicenter 48-week safety study. Global disease severity was measured in more than 500 patients after completion of a 28-day phase 3 pivotal study. Every 4 weeks, global disease severity was assessed to determine whether patients would continue treatment or if there would be cessation of treatment until the next evaluation. On-treatment cycles consisted of twicedaily application of crisaborole to treatable areas, excluding the scalp. The extent of treatment exposure was similar across all age groups, with the mean amount of ointment applied per patient per month being about 133 g. The mean duration for each on- The earlier an infant has skin commensal bacteria, the less likely they are to have AD.
14 Birth modality and breast-feeding versus formula feeding do not seem to affect makeup of the skin microbiome.
14 CoNS strains on healthy skin have shown antimicrobial activity against S aureus.
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Exposure to probiotics in utero can prevent AD in children because of a divergent skin environment. 16 Early exposure to hard domestic water along with a fall/winter birth has been shown to be associated with a higher prevalence of AD in a large Danish cohort. 20 
FLG
Having an FLG mutation might predispose to peanut allergy in children with eczema. 24 LOF mutations in FLG are enough to alter expression of proteins involved in regulation of skin inflammation. 25 Mutational variants can contribute to differences in response to topical therapeutics. 27 Cytokine signaling Individual endotyping and molecular skin signatures can be helpful in guiding AD treatment strategies. 29 Topical therapeutics vary in effects on molecular skin signaling, particularly in regard to IL-12, IL-22, and S100A.
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Serum b-Defensin 2 could potentially be used as a marker of IL-17-driven pathology. 36 IL-4 impairs wound repair responses by repressing fibronectin through gene expression modulation. 38 Patients with AD have increased KLK5 levels in lesional and nonlesional skin. 40 Children with AD have lower circulating B-cell counts than age-matched control subjects but higher CD3 counts. 41 Therapeutics in the pipeline Tralokinumab, an anti-IL-13 agent, at 300 mg every 2 weeks has been shown to significantly improve skin clearance and reduce itch. 44 Nemolizumab, an anti-IL-31 receptor A agent, when given every 4 weeks, has been shown to be beneficial in terms of itch reduction. 47 Ustekinumab, which targets IL-12/IL-23p40 and the T H 2 pathway can provide a benefit in AD treatment in some patients. 48, 49 Safety profiling Dupilumab and crisaborole have shown long-term safety and efficacy in the treatment of AD; however, only crisaborole is approved for use in children.
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CoNS, Coagulase-negative Staphylococcus aureus.
treatment period was also the same among age groups with a mean of 28.4 days, with most patients experiencing at least 2 consecutive on-treatment courses. Treatment-related AEs occurred in 10.3% of patients, and of those, 85.9% were mild to moderate. The most frequently reported treatment-related AEs were worsening of AD, application-site burning, or stinging and application-site infection. Rescue therapy with topical steroids was generally needed for less than 1 month. No additional cutaneous side effects were reported. 52 The conclusion of this study was that crisaborole had a low frequency of treatment-related AEs in children older than 2 years and adults with mild-tomoderate AD.
The long-term safety and efficacy of dupilumab use in more than 700 adults with AD was also investigated in a 1-year, randomized, double-blind, placebo-controlled trial. Patients were randomly assigned to 300 mg of dupilumab weekly or every 2 weeks or placebo for 52 weeks. No attempts were made to stop dupilumab therapy. All patients received concurrent topical steroids; TCIs were only used if body location was inadvisable for topical steroid application. The primary end points included percentage of patients with IGA scores of greater than baseline value, as well as improvement in EASI scores by weeks 16 and 52. Changes were identified in some subjects as early as week 2 of the study. Throughout the study, patients who received dupilumab plus a concurrent topical steroid achieved the best results in both primary end points. Secondary outcomes, such as pruritus, effect on sleep, and quality-of-life scores, were also improved to a greater extent than in the placebo group. There was a greater withdrawal rate from the study by participants in the placebo group, although the majority of participants in the placebo group continued through 16 weeks of the clinical trial. AE rates were similar across treatment groups. Serious AEs were mostly due to discontinuation and subsequent AD flares. The dupilumab groups had greater rates of injection-site reactions related to dose frequency in addition to a greater incidence of conjunctivitis. Most of the conjunctivitis cases were reported as mild and not requiring additional referral or workup.
With regard to infection, overall similar proportions of patients reported herpesvirus infections in each treatment group, but the types of herpectic infections were disparate. Localized infections (oral herpes and herpes simplex) were more frequent in dupilumab users. However, herpes zoster and eczema herpeticum were reported more in the placebo group. Non-herpes-associated skin infections were more common in the placebo group. There were no significant differences between the treatment and control groups in electrocardiographic measures or baseline laboratory markers. 53 A meta-analysis presented as a letter to the editor encompassing dupilumab studies from 2012-2016 also corroborated findings of placebo-like safety profile and improved effectiveness over placebo. 54 Both of these major studies conclude that crisaborole and dupilumab have acceptable safety profiles and are efficacious in the treatment of AD. inhibitor, blocking production of phosphodiesterase 4B and as a result suppressing release of cytokines involved in skin inflammation, including TNF-a. C, Ustekinumab is a human mAb used for treatment of psoriasis and is being investigated for treatment of AD. By blocking IL-12 and IL-23, T-cell activation is prevented, reducing inflammation. D, Tralokinumab is also a human mAb targeting IL-13 and thus preventing B-cell production of IgE and inflammatory effects on epithelium. E, Dupilumab has also been FDA approved for the treatment of AD in adults. Dupilumab is also an mAb targeting IL-4 receptor A, thus blocking both the IL-4 and IL-13 pathways involved in allergic inflammation.
CONCLUSION
Great advances in knowledge and understanding of the skin at the molecular level occurred in 2017, as demonstrated in Table I .* The articles described above represent the dedication of the scientific community to find targeted and effective treatments for a chronic yet common disease. Further characterization of the skin's cellular environment and how this differs among patients has led to a burst of new biologics to add to the currently limited treatment repertoire. Although 2017 clearly provided deeper insight into the pathophysiology and new treatment strategies for AD, surely we will see great strides in the understanding or AD pathophysiology on a molecular level with an expansion of molecular and microbiome-based personalized management of AD in the coming years.
